{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:26:31Z","timestamp":1793661991942,"version":"4.5.1"},"reference-count":101,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/14787210.2025.2473044","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T07:20:03Z","timestamp":1740554403000},"page":"351-358","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges"],"prefix":"10.1080","volume":"23","author":[{"given":"Daniele","family":"Focosi","sequence":"first","affiliation":[{"name":"Pisa University Hospital","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Carlo Poma Hospital","place":["Mantova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00119-23"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29310"},{"key":"e_1_3_6_6_1","unstructured":"FDA. Fact sheet VEKLURY\u00ae (remdesivir) for injection for intravenous use. [cited 2025 Mar 3]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214787Orig1s000lbl.pdf"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2024.03.008"},{"key":"e_1_3_6_8_1","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization for PaxlovidTM. 2024 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/155050\/download"},{"key":"e_1_3_6_9_1","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization for lagevrio\u2122 (molnupiravir) capsules. 2024 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/155055\/download"},{"key":"e_1_3_6_10_1","unstructured":"FDA. Stromectol\u00ae (IVERMECTIN). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050742s026lbl.pdf"},{"key":"e_1_3_6_11_1","unstructured":"FDA. Plaquenil\u00ae hydroxychloroquine sulfate tablets usp. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/009768s037s045s047lbl.pdf"},{"key":"e_1_3_6_12_1","volume-title":"Regkirona, inn-regdanvimab - European Medicines Agency","author":"EMA","year":"2021","unstructured":"EMA. Regkirona, inn-regdanvimab - European Medicines Agency. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/regkirona"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101533"},{"key":"e_1_3_6_14_1","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization of Pemgarda. 2024 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/177067\/download"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v10i1.752"},{"key":"e_1_3_6_16_1","unstructured":"FDA. Fact sheet for health care providers emergency use authorization (EUA) of Regen-Cov\u00ae (casirivimab and imdevimab). 2022 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119407"},{"key":"e_1_3_6_18_1","unstructured":"FDA. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab. 2021 [cited 2025 Mar 3]. https:\/\/pi.lilly.com\/eua\/bamlanivimab-eua-factsheet-hcp.pdf"},{"key":"e_1_3_6_19_1","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. 2022 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/156152\/download"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01137-23"},{"key":"e_1_3_6_21_1","unstructured":"FDA. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. 2022 [cited 2025 Mar 3]. https:\/\/pi.lilly.com\/eua\/bam-and-ete-eua-factsheet-hcp.pdf"},{"key":"e_1_3_6_22_1","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization for sotrovimab. 2023 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/149534\/download?attachment?attachment"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14061334"},{"key":"e_1_3_6_24_1","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization for evusheld\u2122 (tixagevimab co-packaged with cilgavimab). 2023 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/154701\/download"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42140"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309003"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40020245.x"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100694"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00102-14"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102359"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301425"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105450"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1611"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2023.12.004"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02597-1"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00519-0"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00897-7"},{"key":"e_1_3_6_41_1","unstructured":"Martinez DR Moreira FR Zweigart MR et al. Efficacy of the oral nucleoside prodrug GS-5245 (obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential. bioRxiv. 2023:2023.06.27.546784."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00577-7"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000034"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.14740\/cr1493"},{"key":"e_1_3_6_45_1","unstructured":"Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK-4482-001). [cited 2022 Oct 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04575584"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1086\/444389"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2003.03308.x"},{"key":"e_1_3_6_49_1","doi-asserted-by":"crossref","unstructured":"Tippabhotla S Lahiri S Raju D et al. Efficacy and safety of Molnupiravir for the treatment of non-hospitalized adults with mild COVID-19: a randomized open-label parallel-group phase 3 trial 2022. [cited 2022 Feb 24]. Available from: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4042673","DOI":"10.2139\/ssrn.4042673"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29642"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06649-6"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26760-4"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208822"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100991"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12080887"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16010003"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2024.100581"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199906)58:2<174::AID-JMV12>3.0.CO;2-X"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15051048"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2404555"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00575-3"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00573-X"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1192"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00744-2"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.06.013"},{"key":"e_1_3_6_66_1","doi-asserted-by":"crossref","unstructured":"Planas D Staropoli I Michel V et al. Distinct evolution of SARS-CoV-2 omicron XBB and BA.2.86 lineages combining increased fitness and antibody evasion. bioRxiv. 2023:2023.11.20.567873.","DOI":"10.1101\/2023.11.20.567873"},{"key":"e_1_3_6_67_1","doi-asserted-by":"crossref","unstructured":"Li P Faraone JN Hsu CC et al. Neutralization and stability of JN.1-derived LB.1 KP.2.3 KP.3 and KP.3.1.1 subvariants. bioRxiv. 2024:2024.09.04.611219.","DOI":"10.1101\/2024.09.04.611219"},{"key":"e_1_3_6_68_1","doi-asserted-by":"crossref","unstructured":"Yao T Ma Z Lan K et al. Neutralizing activity and viral escape of Pemivibart by SARS-CoV-2 JN.1 sublineages. bioRxiv. 2024:2024.11.08.622746.","DOI":"10.1101\/2024.11.08.622746"},{"key":"e_1_3_6_69_1","doi-asserted-by":"crossref","unstructured":"Wang Q Guo Y Mellis IA et al. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. bioRxiv. 2024:2024.11.17.624037.","DOI":"10.1101\/2024.11.17.624037"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000174456.08992.2b"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2410203"},{"key":"e_1_3_6_72_1","doi-asserted-by":"crossref","unstructured":"Powers C Williams B Kreher A et al. Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage. bioRxiv.2024:2024.11.11.623127.","DOI":"10.1101\/2024.11.11.623127"},{"key":"e_1_3_6_73_1","doi-asserted-by":"crossref","unstructured":"Liu J Yu Y Yang S et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1 NP.1 and LP.8.1. bioRxiv. 2024:2024.12.27.630350.","DOI":"10.1101\/2024.12.27.630350"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14091999"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16020217"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.04.012"},{"key":"e_1_3_6_77_1","doi-asserted-by":"crossref","unstructured":"Wolfe CR Cohen J Mahoney K et al. Safety and efficacy of Pemivibart a long-acting monoclonal antibody for prevention of symptomatic COVID-19: interim results from the CANOPY clinical trial. medRxiv. 2024:2024.11.11.24317127.","DOI":"10.1101\/2024.11.11.24317127"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00804-1"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-003-0290-7"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3428"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111845"},{"key":"e_1_3_6_82_1","unstructured":"FDA.RE: emergency use authorization 122. 2001 [cited 2025 Mar 3]. https:\/\/www.fda.gov\/media\/177068\/download"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.8592"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33864-y"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13498"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14020214"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae408"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28997"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13627"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2260040"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28277"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6160"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3041"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05609-w"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae371"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108959"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/life13010134"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.07.020"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17701"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00503-w"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105613"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2414957121"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14091207"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2025.2473044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:05:12Z","timestamp":1748833512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2025.2473044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/14787210.2025.2473044"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2025.2473044","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}